📰 Resented News
Page 15 - Resented News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Resented. Real-time updates on events, politics, business and more.
May 4, 2023
Here are the questions presented in the Inderes analytics platform to Otto Pukk, President and CEO of Incap Corporation, regarding the 1Q 2023 results, and answers for these... | May 4, 2023
May 4, 2023
– Petosemtamab clinical update presented at the American Association of Cancer Research Annual Meeting 2023– Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration... | May 4, 2023
May 3, 2023
Mowi ASA hereby invites you to the presentation of the results for the first quarter 2023 at Hotel Continental, Stortingsgaten 24/26, 0117 Oslo, Norway. The results will be presented in English... | May 3, 2023
May 3, 2023
Emerson today reported results for its second quarter ended March 31, 2023 and updated its full year outlook for fiscal 2023, which are presented on a continuing operations basis. Emerson also... | May 3, 2023
May 3, 2023
Research Presented at the American Urological Association Annual Meeting Confirms Five-Year Durability of UroLift® System and Highlights Low Rates of Procedural ComplicationsWAYNE, Pa., May 03,... | May 3, 2023
May 3, 2023
95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023 -- Microbot Medical Inc. , the... | May 3, 2023
May 3, 2023
A slowdown in business with major customers put pressure on Teamviewer shares on Wednesday. The paper of the software specialist, which had presented its quarterly report this morning, lost 11.4... | May 3, 2023
May 3, 2023
– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive... | May 3, 2023
May 3, 2023
The material resolutions passed at TF banks Annual General Meeting earlier today on 3 May 2023 are presented below. The meeting was held in Wigge & Partners Advokat KBs offices in Stockholm and... | May 3, 2023
May 3, 2023
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to